{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-004542","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.353642+00:00","generated_at":"2026-05-16T02:02:17.162892+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%","bullets":["CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.","Annual target bonus opportunity raised from 40% to 50% of base salary.","Amendment effective Feb 17, 2026; equity vesting acceleration unchanged.","No other changes to existing employment agreement terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-004542","json":"https://secwatch.observer/filing/0001437749-26-004542.json","markdown":"https://secwatch.observer/filing/0001437749-26-004542.md","text":"https://secwatch.observer/filing/0001437749-26-004542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926004542/0001437749-26-004542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926004542/phio20260216_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:02:17.162892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}